Strategic Collaborations BioArctic relies on global pharma partnerships to bring its BrainTransporter technology and neurodegenerative programs to market, presenting opportunities for strategic co-development, licensing deals, or co-promoted therapies with large pharma and specialty biotech players.

Leqembi Growth The Leqembi (lecanemab) collaboration and its expanding approvals drive recurring royalty revenue and potential upsell of adjunct therapies or companion diagnostics, suggesting sales opportunities around integration with neurology clinics, infusion centers, and insurance partnerships.

Early Access Channels China's NHSA inclusion of Leqembi in the commercial insurance list and priority reviews for new administration routes indicate a need for market access support, payer strategy services, and localized regulatory guidance to accelerate adoption in major growth markets.

Financial Position Record 2025 results and strong cash position enable BioArctic to pursue partnerships and new projects; sales outreach can emphasize co-development opportunities, milestone-driven partnerships, and technology licensing around BrainTransporter and compound programs.

Neuropipeline Opportunities A diversified portfolio in Alzheimer's, Parkinson's, and ALS, plus a broad project pipeline, opens cross-selling potential for neuroscience diagnostics, biomarker collaborations, and clinical trial services with CROs, contract work, and pharma sponsors seeking innovative CNS solutions.